The PARIS Trial

Effect of Early High-Flow Nasal Oxygen vs Standard ... - JAMA Network

The PARIS 2 trial was an investigator-initiated randomized clinical trial to evaluate the role of high-flow oxygen therapy compared with ...

Effect of Early High-Flow Nasal Oxygen vs Standard ... - PubMed

... The PARIS-2 Randomized Clinical Trial. JAMA. 2023 Jan 17;329(3):224-234. doi: 10.1001/jama.2022.21805. Authors. Donna Franklin 1 2 3 4 5 , Franz E Babl ...

Inside the Paris attacks trial: 'A man stood up and said - The Guardian

Central Paris, Île de la Cité. The trial that gets under way today will not be the Nuremberg of terrorism, as some have said: whereas high Nazi ...

Early high flow nasal cannula therapy in bronchiolitis, a prospective ...

The trial is registered with the Australian and New Zealand Clinical Trials Registry ACTRN12613000388718 (registered on 10 April 2013).

Multicentre, randomised trial to investigate early nasal high—flow ...

The PARIS 2 trial is a multicentre, randomised trial recruiting 1512 children aged 1 to 4 years requiring hospital admission for AHRF. The study will be ...

The PARIS-2 Randomized Clinical Trial (JAMA)

The speaker presents the results of a study on the use of nasal high flow in children with acute hypoxemic respiratory failure.

The PARIS Trial: HFNC in Infants with Bronchiolitis - REBEL EM

The PARIS Trial: This trial evaluated early high-flow oxygen therapy vs standard oxygen therapy in infants with bronchiolitis and hypoxemia ...

Blow some Os up that nose? The PARIS 2 RCT - First10EM

Although the original PARIS trial was technically positive, the results did not look great to me. Here, we will cover the PARIS 2 trial, a ...

A Randomized Trial of High-Flow Oxygen Therapy in Infants with ...

Infants in the standard-therapy group received supplemental oxygen through a nasal cannula, up to a maximum of 2 liters per minute, to maintain ...

PARIS 2 research findings - Wesley Research Institute

PARIS 2 is the world's first large-scale clinical trial in children aged under five years presenting to hospital emergency departments with a respiratory ...

V13 by Emmanuel Carrère review – harrowing account of the Paris ...

V13 by Emmanuel Carrère review – harrowing account of the Paris attacks trial. A chronicle of the largest criminal case in French history from a ...

PARIS 2 Trial – PREDICT

This study aims to conduct a multi-centre trial to assess which infants and children with acute hypoxemic respiratory failure (AHRF) benefit ...

Paris attacks trial - Wikipedia

The trial in Paris, France, of twenty men accused of involvement in the Paris terrorist attacks of 13 November 2015, which killed 130 people and injured ...

Judgement of Paris - Wikipedia

Three guests, Hera, Athena and Aphrodite, after some disputation, agreed to have Paris of Troy choose the fairest one. Paris chose Aphrodite, she having bribed ...

Pediatric Respiratory Failure No Better Off With Early High-Flow ...

... the PARIS-2 trial showed. In fact, hospital stays were actually significantly longer in patients, ages 1-4 years, randomized to high-flow ...

Terrorism trial opens in Paris for Islamists accused of beheading ...

Eight people went on trial in Paris on terrorism charges on Monday over the gruesome 2020 murder of the French teacher who had shown his ...

High flowing controversy: A return ticket to PARIS

PARIS is a trial of a strategy of immediate HFNC for hypoxaemia in bronchiolitis, vs a strategy of rescue HFNC for hypoxaemia when standard ...

World-first study signals change for child respiratory treatments

PARIS-2 is the world's first large-scale clinical trial in children aged one to five years who present at a hospital emergency department ...

SGEM #401: Hey Ho! High Flow vs Standard Oxygen Therapy for ...

Case: A 14-month-old boy presents to the emergency department (ED) with two days of upper respiratory symptoms and respiratory distress. He has ...

PARIS on Country - Wesley Research Institute

New PARIS on Country project aims to reduce these transfers by half. “Based on the evidence from two world-first clinical trials — PARIS 1 ...